BillionToOne enters the post-earnings stretch with a striking divergence: short sellers have been covering rapidly, but options traders have turned the most defensively positioned they have been in months.
The most dramatic shift in the lending market is the collapse of the cost to borrow. A month ago, borrowing BLLN shares cost north of 175% annualised — among the most expensive borrows in the diagnostics universe. That rate has crashed to 26.9%, down roughly 85% over 30 days. The move coincides with a rapid short-covering episode: short interest as a percentage of free float fell from a peak of around 8.7% on May 5 to 6.5% by May 12, as roughly 514,000 net shares were covered over the week. Availability, at just 24% of current short interest, remains tight — meaning for every four shares already lent out, only one is still available — but the direction of travel is clearly easing versus the fully-locked conditions that prevailed through most of April, when availability was at zero and the borrow market was entirely seized up.
Options positioning tells a sharply different story. Demand for downside protection has spiked: the put/call ratio jumped to 1.04 on May 12, more than 2.7 standard deviations above its 20-day average of 0.65. That is the highest defensive reading outside of March 2026, when the ratio briefly touched 1.63. With the stock up 18% on the week after a +16% single-day reaction to Q1 earnings on May 6, the options hedging activity reads as investors locking in gains rather than expressing fresh bearish conviction — but it is worth noting the divergence against the covering trend in the short book.
The Street is broadly constructive, and the earnings release prompted a swift rerate. JP Morgan raised its target to $125 from $120, maintaining Overweight, while Guggenheim lifted to $120 from $100 just this week — its second target revision in six weeks, now back to where it stood before the March cut. BTIG trimmed to $130 from $140 after the print, keeping its Buy, suggesting the firm sees the post-earnings rally as having absorbed some of the upside. The mean consensus target is $117.71, implying modest upside from the current $94.23 close. Valuation has re-rated sharply: the P/E multiple has compressed roughly 26 points over the past 30 days, while EV/EBITDA contracted by 31.6x over the same period — both reflecting earnings growth rather than multiple expansion. The ORTEX short score, while still elevated at 71.3, has been falling steadily from a peak of 84.5 on May 1, tracking the short cover.
The institutional register reflects a relatively concentrated ownership base with several recent entrants building positions. Baillie Gifford added 415,000 shares as of Q1, Neuberger Berman initiated a new stake of 701,000 shares, and T. Rowe Price added 586,000 shares — all reported through March 31. Those additions predate the post-earnings rally and represent meaningful endorsements from long-only names. Civilization Ventures and NVP Associates also appear as new Q4 holders. The top two holders — Hummingbird Ventures at 17.1% and NeoTribe Ventures at 9.5% — are venture-style investors, a reminder that the free float is relatively thin against a market cap now approaching $3.9 billion.
The next earnings event is scheduled for June 9. In the only comparable prior release with full data — the March 4 Q4 print — the stock fell 13.2% the following day and dropped 19% over five days. The May 6 print produced the opposite, with a 16.3% one-day gain. With the borrow market still tighter than normal, the short score still in elevated territory, and options hedging at a multi-month high, the June print will be watched closely for whether the growth acceleration that drove the May re-rating has continued.
See the live data behind this article on ORTEX.
Open BLLN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
